SmartLipids in Drug Delivery: Redefining the Third Generation of Lipid Nanocarriers for Clinical and Industrial Translation

Abstract

SmartLipids represent the third generation of lipid-based nanocarriers, emerging as a transformative innovation in modern drug delivery and formulation science. Evolving from solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), SmartLipids overcome key limitations such as low drug loading, polymorphic instability, and limited scalability. Characterized by a “chaotic” matrix of 5– 10 structurally diverse lipids, SmartLipids enable high encapsulation efficiency, enhanced physical and chemical stability, tunable drug release, and improved penetration and bioavailability for both lipophilic and amphiphilic molecules. This comprehensive review elucidates their rational design principles, formulation strategies, and key physicochemical and biological characterization parameters, supported by recent preclinical findings demonstrating superior cytocompatibility, permeability, and controlled release performance. Furthermore, we discuss the industrial translation of SmartLipids under Quality by Design (QbD) frameworks, their regulatory prospects, and their expanding applications beyond cosmetics, spanning oral, mucosal, and gene delivery systems. Collectively, SmartLipids bridge the gap between bench-scale innovation and clinical translation, offering a versatile, stable, and scalable platform for next-generation nanomedicines.

Introduction

Lipid nanocarriers with a submicron particle size of less than 1000 nm have now long been utilized for having the potential of efficient and controlled drug delivery to the target sites or organs, circumvent the challenges associated with conventional drug delivery strategies.1,2 Lipid-based drug delivery systems like lipid nanoparticles (LNPs) have been investigated, and its advanced drug delivery techniques such as Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs), have rapidly gained recognition in the scientific community.3,4 SLNs are the first-generation LNPs;5 they were designed to overcome the drawbacks of conventional colloidal carriers, with the advantages of protecting the drug from the gut’s harsh environment and improving the bioavailability and controlled drug delivery at targeted sites.6,7 Even with these benefits, it still has certain shortcomings, like polymorphic transitions, reduced drug load, and leakage of drugs during storage.7 These disadvantages became the reason for developing a second generation of LNPs, which are NLCs with the beneficial effects of stability and enhanced loading capacity due to their structural composition.8,9

The latest third generation of LNPs, ie., SmartLipids, was introduced in 2014 to cover the limitations of NLCs, such as poor adhesion, which ultimately affects the drug’s absorption and its bioavailability.10–13 SmartLipids are the specialized version of NLCs that primarily differ in composition, as they attain a 5–10 lipids blend, either solid lipids only or with limited incorporation of oil, while NLCs only hold one liquid lipid and one solid lipid.14 Consequently, this chaotic blend of SmartLipids not only supports the loading capacity of actives but also protects them from degradation and increases chemical stability. Overall, the combination of firm drug inclusion, high drug loading aspects and reduced or absence of polymorphic transition makes SmartLipids a highly potential and attractive nanocarrier for pharmaceutical and cosmetic active ingredients.15 They also improve drugs’ penetration and bioavailability, serve as a natural skin barrier for restoration, hinder chemically labile actives’ degradation, control the drug release profile, and increase cellular uptake. All these benefits render SmartLipids a promising nanocarriers for efficient drug delivery of lipophilic/amphiphilic molecules.14,16 Due to the combination of versatile lipids, these nanocarriers chaotically arrange themselves, which renders them for high drug loading and reduced tendency to form ordered structures, thereby providing better stabilization for sensitive active substances.17

The present review provides a detailed overview of SmartLipids, ie., an emerging class of lipid-based nanocarriers. It highlights their historical advancement from SLNs and NLCs, designing principles, formulation strategies, characterization and evaluation parameters, examples of commercially available SmartLipids, and future trends. It helps to provide the existing trends that were employed for improving the bioavailability of different active ingredients by adopting this advanced lipid-based drug delivery system.

Download the full article as PDF here SmartLipids in Drug Delivery

or continue reading here

Table 2 List of Solid Lipids Communicated for SmartLipids Production

Hashmi AR, Zahra F, Sekar M, Al Hamod M, Al Hamood N, Begum MY, Molugulu N, Wong LS, Kumarasamy V. SmartLipids in Drug Delivery: Redefining the Third Generation of Lipid Nanocarriers for Clinical and Industrial Translation. Int J Nanomedicine. 2026;21:1-29, https://doi.org/10.2147/IJN.S578218

Are you looking for excipients in commercial quantities?